Active Monitoring of Adverse Reactions Related to Anti-tumor Targeted Drugs

Zhao Qing

doi:10.3969/j.issn.1004-5775.2025.04.004

Abstract：Objective:To explore the results of active monitoring of adverse reactions related to anti-tumor targeted drugs.Methods:A retrospective analysis was conducted on 66 cases of adverse reactions to anti-tumor drugs admitted to the hospital from January 2023 to December 2023.General patient information,types of anti-tumor drugs,administration routes,and organs affected by adverse reactions were collected,and the results were analyzed.Results:The highest proportion of adverse reactions to anti-tumor targeted drugs occurred between the ages of 50 and 70,accounting for 51.52％.The lowest proportion of adverse reactions to anti-tumor targeted drugs occurred under the age of 30,accounting for 4.55％.The probability of adverse reactions of anti-tumor targeted drugs in men between 30 and 70 years old was lower than that in women.Among drug types,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)had the highest proportion of anti-tumor targeted drug adverse reactions(66.67％),while anti-vascular drugs had the lowest proportion of anti-tumor targeted drug adverse reactions(6.06％).Among drug types,EGFR-TKI showed the highest proportion of anti-tumor targeted drug adverse reactions(31.82％).Adverse reactions caused by anti-tumor targeted drugs can affect multiple organs and tissues,with gastrointestinal reactions being the most common,accounting for 33.33％of patients,followed by skin,liver and kidney,oral and nasal mucosa,and lungs,accounting for 31.82％,15.15％,12.12％,and 7.58％,respectively.Conclusion:For patients who experience adverse reactions to clinical anti-tumor drugs,it is necessary to pay attention to the use of EGFR-TKI for treatment,prepare a prognosis plan in advance,ensure the efficacy while also ensuring medication safety.